Tscan Therapeutics, Inc. ( (TCRX) ) has released its Q2 earnings. Here is a breakdown of the information Tscan Therapeutics, Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TScan Therapeutics, Inc. is a clinical-stage biotechnology company specializing in T cell receptor-engineered T cell therapies for cancer treatment, with a focus on hematologic malignancies and solid tumors. In its second quarter 2025 financial report, TScan Therapeutics highlighted significant advancements in its clinical programs, including the anticipated dosing of solid tumor patients with multiplex TCR-T therapies and the upcoming presentation of two-year relapse data from its ALLOHA Phase 1 trial. The company reported a substantial increase in revenue to $3.1 million, driven by its collaboration with Amgen, while research and development expenses rose to $32.6 million due to expanded manufacturing capabilities. Despite a net loss of $37 million, TScan maintains a strong cash position of $218 million, expected to fund operations into early 2027. Looking ahead, TScan aims to initiate a registrational trial for its lead candidate TSC-101 and file an IND for a new therapy, reflecting a strategic focus on advancing its pipeline and enhancing manufacturing efficiency.